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Over the past decade, health expenditure has increased 
year on year as a proportion of national income 
(Figure). This unsustainable increase in healthcare 
expenditure has consistently outstripped inflation 
and is expected to increase even further. Healthcare 
inflation is driven by many factors. First, the ageing 
population; second, therapeutic advances over recent 
years have rendered many previously fatal diseases 
survivable, turning them into chronic, manageable 
diseases; and third, increasing requirements for 
scientific rigour and the growing regulation of clinical 
trials have greatly increased the cost to industry of 
bringing novel interventions to the clinic. Industry is in 
turn dependent on considerable revenue to underpin 
a sustainable development pipeline. 
Solutions to improve healthcare do not have to be 
costly and even high-tech solutions might eventually 
lead to a reduction of costs. It will, however, require 
close collaboration between all stakeholders, 
including governmental bodies, academia, industry 
and entrepreneurs among others, in combination 
with a creative open-minded approach to future 
challenges. Open innovation is an example of an 
approach that offers huge potential to address 
these healthcare challenges. In contrast to a closed 
innovation model, where the technology is developed 
within the company and the market is the only 
outcome, in an open innovation model, technology 
can be insourced from elsewhere, and developed 
technology from within the company can be out-
licensed or spun out by other (start-up) companies. 
Open innovation harnesses networks to expand the 
number of talented people contributing ideas and 
working on the same problems. 
Below, some options for the cost-efficient 
improvement of healthcare that might also create 
opportunities for the UK’s life science sector are 
explored.
1) Scientific advances over recent years have enabled 
in-depth characterisation of disease never before 
possible. Genomics, metabolomics and proteomics 
are able to map the complexity of systems in biology 
and disease. A systems approach 
has the potential not only to link 
genes or proteins to diseases, but 
also to understand their cause more 
fully. Already these approaches 
have yielded new therapeutic 
targets and pathophysiological 
insights, and have started to drive 
a change of focus from treatment 
to prevention and early detection 
of disease. These technologies 
also pave the way for stratified 
or personalised medicine, where 
diseases are managed in relation 
to the characteristics of each 
individual patient, in contrast to the 
conventional model of population 
level treatments. By convention, 
all patients with a disease receive a 
particular treatment. Some would 
respond in full, some in part, but 
some would show no response 
or may suffer complications from the intervention 
without any therapeutic benefit. Stratified medicine 
seeks to identify these groups a priori and to tailor 
treatment accordingly. The huge expansion in, and 
integration of scientific, medical, epidemiological and 
public health data could also uncover to clinicians 
and researchers off-target effects of established 
treatments. These may be of therapeutic benefit, 
may pertain to previously unrecognised side effects, 
or may relate to psychosocial factors. This opens up 
many opportunities for the pharmaceutical industry, 
as the relative efficacy of drugs improves with more 
precise patient targeting. 
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For healthcare providers, the decision to utilise novel 
innovations depends increasingly on their affordability. 
It is therefore important that innovations are directed 
at the areas of greatest need, and at diagnoses or 
interventions where their application is most likely 
to result in patient benefit and cost savings. As an 
example, the cost of dialysis for kidney failure in the 
UK is estimated at £35,000 per year [1]. Interventions 
that prevent or delay the onset of kidney failure may 
therefore result in considerable savings.
2) A myriad of low technology or technology-free 
solutions exist that have the potential to improve 
healthcare. For example, lifestyle interventions are 
perhaps not all new but can have a dramatic impact on 
health outcomes and thereby reduce costs. Exercise, 
diet and smoking cessation can all dramatically 
impact on cardiovascular risk.
3) Another area of focus, recently emphasised by the 
Medical Research Council, is the development of new 
uses for existing interventions. One example of this 
is the drug thalidomide, withdrawn after its use for 
pregnancy-related vomiting resulted in catastrophic 
limb deformities in newborns. Recently, thalidomide 
has re-entered clinical practice as a treatment for the 
blood disorder myeloma.
4) Much can be gained by re-analysing existing 
healthcare processes and developing creative 
solutions in combination with existing technology. 
This approach has been successfully used to promote 
screening for bowel cancer in the United States. 
“Gutcheck” is a communication toolkit that supports 
shared decision-making conversations about 
colon cancer screening [2, 3]. Indeed there is a rapid 
expansion of digital solutions that combine the use 
of computational technologies, communication 
media, and smart devices to manage healthcare. One 
interesting aspect of digital healthcare is the change 
in emphasis to a model of patient self-management, 
which reduces the burden of care on providers. In the 
United Kingdom, approximately 44% of the healthcare 
budget is spent on salaries [4]. Any approaches that 
reduce the time demands on healthcare staff are 
therefore particularly attractive to commissioners.
Finally, enhancing the logistics of where and by whom 
healthcare is provided is a key priority to relieve the 
increasing pressure on healthcare in an environment 
where increasing financial constraints and an ever-
expanding patient population co-exist. The pooling 
of resources and expertise in specialised clinics for 
relatively common conditions can increase the quality 
of care, increase efficiency of specialist services, and 
relieve pressure on general hospitals. Furthermore, 
active patient participation, specifically in the field of 
rare diseases, could greatly add value by encouraging 
patients to provide feedback on their treatments 
and symptoms, effectively using the patient as a 
biosensor to monitor and improve patient care. One 
example that incorporates many of these aspects is 
the recently opened Alexander Monro Hospital in The 
Netherlands, which focuses solely on the treatment of 
breast cancer [5]. 
Understanding and implementing innovations for 
healthcare need not necessarily drive up costs but 
could have the inverse effect while also improving 
healthcare quality. Current healthcare challenges 
are very varied and the solutions to these challenges 
are likely to be equally diverse. Government has a 
very important role to play; smart investments and 
rigorous yet flexible regulation will prove crucial to 
meeting the challenges of providing sustainable, high 
quality healthcare for the future.
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